ADB-HEXINACA

ADB-HEXINACA
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B; US: Schedule I;
Identifiers
	IUPAC name N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-hexyl-1H-indazole-3-carboxamide;
CAS Number	3047777-38-5 ;
PubChem CID	163191674;
ChemSpider	109107958;
CompTox Dashboard (EPA)	DTXSID701038279 ;
Chemical and physical data
Formula	C20H30N4O2
Molar mass	358.486 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N[C@@H](C(C)(C)C)C(N)=O)C1=NN(CCCCCC)C2=C1C=CC=C2;
	InChI InChI=1S/C20H30N4O2/c1-5-6-7-10-13-24-15-12-9-8-11-14(15)16(23-24)19(26)22-17(18(21)25)20(2,3)4/h8-9,11-12,17H,5-7,10,13H2,1-4H3,(H2,21,25)(H,22,26)/t17-/m1/s1; Key:PZMLDAGKYPJWHJ-QGZVFWFLSA-N;

ADB-HEXINACA (also known as ADB-HINACA and ADMB-HEXINACA) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first appearing in early 2021. It is a longer chain homologue of previously encountered synthetic cannabinoid compounds such as ADB-BUTINACA and ADB-PINACA.^[1]^[2] The pharmacology of ADB-HEXINACA and numerous analogues at CB1 and CB2 receptors has been reported.^[3]

References

^ Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, et al. (November 2021). "The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons". Drug Testing and Analysis. 14 (4): 634–652. doi:10.1002/dta.3203. PMID 34811926. S2CID 244490343.
^ Gilbert N, Costello A, Ellison JR, Khan U, Knight M, Linnell MJ, et al. (December 2021). "Synthesis, characterisation, detection and quantification of a novel hexyl-substituted synthetic cannabinoid receptor agonist: (S)-N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-hexyl-1H-indazole-3-carboxamide (ADB-HINACA)" (PDF). Forensic Chemistry. 26: 100354. doi:10.1016/j.forc.2021.100354.
^ Sparkes E, Timmerman A, Markham JW, Boyd R, Gordon R, Walker KA, et al. (April 2024). "Synthesis and Functional Evaluation of Synthetic Cannabinoid Receptor Agonists Related to ADB-HEXINACA". ACS Chemical Neuroscience. 15 (9): 1787–1812. doi:10.1021/acschemneuro.3c00818. PMID 38597712.

[1] Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, et al. (November 2021). "The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons". Drug Testing and Analysis. 14 (4): 634–652. doi:10.1002/dta.3203. PMID 34811926. S2CID 244490343.

[2] Gilbert N, Costello A, Ellison JR, Khan U, Knight M, Linnell MJ, et al. (December 2021). "Synthesis, characterisation, detection and quantification of a novel hexyl-substituted synthetic cannabinoid receptor agonist: (S)-N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-hexyl-1H-indazole-3-carboxamide (ADB-HINACA)" (PDF). Forensic Chemistry. 26: 100354. doi:10.1016/j.forc.2021.100354.

[3] Sparkes E, Timmerman A, Markham JW, Boyd R, Gordon R, Walker KA, et al. (April 2024). "Synthesis and Functional Evaluation of Synthetic Cannabinoid Receptor Agonists Related to ADB-HEXINACA". ACS Chemical Neuroscience. 15 (9): 1787–1812. doi:10.1021/acschemneuro.3c00818. PMID 38597712.

[1]

[2]

[3]

See also

References